Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.45 USD -2.03% Intraday chart for Corvus Pharmaceuticals, Inc. +3.57% -17.61%
Apr. 09 Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CI
Mar. 20 Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 160 99.9 112.2 39.57 86.31 71.11 - -
Enterprise Value (EV) 1 160 99.9 112.2 39.57 86.31 71.11 71.11 71.11
P/E ratio -3.42 x -17.8 x -2.34 x -0.96 x -3.14 x -2.54 x -2.3 x -1.75 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - - 5.27 x
EV / Revenue - - - - - - - 5.27 x
EV / EBITDA - - - - - - - -
EV / FCF -4,373,148 x - -3,055,059 x -1,449,893 x - - - -
FCF Yield -0% - -0% -0% - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 29,405 28,062 46,548 46,554 49,039 49,039 - -
Reference price 2 5.440 3.560 2.410 0.8500 1.760 1.450 1.450 1.450
Announcement Date 3/5/20 3/25/21 3/10/22 3/28/23 3/19/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 13.48
EBITDA - - - - - - - -
EBIT 1 -48.85 -43.76 -38.63 -32.56 -23.41 -33.1 -45.62 -62.3
Operating Margin - - - - - - - -462.08%
Earnings before Tax (EBT) 1 -46.67 -5.995 -43.24 -41.31 -27.03 -32.94 -43.4 -67.15
Net income 1 -46.67 -5.995 -43.24 -41.31 -27.03 -33.1 -45.27 -62.07
Net margin - - - - - - - -460.36%
EPS 2 -1.590 -0.2000 -1.030 -0.8900 -0.5600 -0.5700 -0.6300 -0.8267
Free Cash Flow -36.58 - -36.72 -27.29 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/5/20 3/25/21 3/10/22 3/28/23 3/19/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -9.047 -6.81 -7.413 -7.013 -12.47 -5.666 -6.574 -5.622 -5.56 -5.651 -6.413 -7.092 -8.279 -9.082
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -10.67 -9.236 -8.297 -8.363 -14.83 -9.816 -7.873 -6.503 -6 -6.653 -7.36 -7.34 -8.58 -9.65
Net income 1 -10.67 -9.236 -8.297 -8.363 -14.83 -9.816 -7.873 -6.503 -6 -6.653 -6.557 -7.031 -8.159 -9.005
Net margin - - - - - - - - - - - - - -
EPS 2 -0.2400 -0.2000 -0.1800 -0.1800 -0.3200 -0.2100 -0.1700 -0.1400 -0.1200 -0.1400 -0.1300 -0.1267 -0.1467 -0.1600
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/1/21 3/10/22 5/5/22 8/8/22 11/3/22 3/28/23 5/8/23 8/8/23 11/7/23 3/19/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -36.6 - -36.7 -27.3 - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.03 - 0.01 0.27 - - - -
Capex / Sales - - - - - - - -
Announcement Date 3/5/20 3/25/21 3/10/22 3/28/23 3/19/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.45 USD
Average target price
7.5 USD
Spread / Average Target
+417.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CORVUS PHARMACEUTICALS, INC. Stock Corvus Pharmaceuticals, Inc.
-17.61% 71.11M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. Financials Corvus Pharmaceuticals, Inc.